These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38712907)

  • 1. Challenges with drug efficacy prediction of in vitro models of biofilms infecting cystic fibrosis airway.
    Sousa AM; Pereira MO
    Expert Opin Drug Discov; 2024 Jun; 19(6):635-638. PubMed ID: 38712907
    [No Abstract]   [Full Text] [Related]  

  • 2. New antimicrobials in the management of cystic fibrosis.
    Høiby N
    J Antimicrob Chemother; 2002 Feb; 49(2):235-8. PubMed ID: 11815562
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.
    Jakobsen TH; Bjarnsholt T; Jensen PØ; Givskov M; Høiby N
    Future Microbiol; 2013 Jul; 8(7):901-21. PubMed ID: 23841636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Antibiotics against Pseudomonas aeruginosa in an
    Diaz Iglesias Y; Van Bambeke F
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimicrobial Treatment Provides a Competitive Advantage to Mycobacterium abscessus in a Dual-Species Biofilm with Pseudomonas aeruginosa.
    Rodríguez-Sevilla G; Crabbé A; García-Coca M; Aguilera-Correa JJ; Esteban J; Pérez-Jorge C
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 8. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Güzel C; Gerçeker AA
    J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of alginate lyase on the gentamicin resistance of Pseudomonas aeruginosa in mucoid biofilms.
    Germoni LA; Bremer PJ; Lamont IL
    J Appl Microbiol; 2016 Jul; 121(1):126-35. PubMed ID: 27061817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.
    Lozano C; Azcona-Gutiérrez JM; Van Bambeke F; Sáenz Y
    PLoS One; 2018; 13(9):e0204167. PubMed ID: 30212579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.
    Nichols DP; Durmowicz AG; Field A; Flume PA; VanDevanter DR; Mayer-Hamblett N
    Ann Am Thorac Soc; 2019 May; 16(5):534-539. PubMed ID: 30658043
    [No Abstract]   [Full Text] [Related]  

  • 16. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron metabolism in
    Zhang Y; Pan X; Wang L; Chen L
    J Drug Target; 2021 Mar; 29(3):249-258. PubMed ID: 32969723
    [No Abstract]   [Full Text] [Related]  

  • 19. Pseudomonas aeruginosa colonization in the upper and lower airways of a child with cystic fibrosis: a father's meticulous approach to successful eradication.
    Mainz JG; Baier M; Jaudszus A; Tabori H; Ribeiro JD; Lorenz M
    J Bras Pneumol; 2019 Oct; 45(6):e20190191. PubMed ID: 31618301
    [No Abstract]   [Full Text] [Related]  

  • 20. Clues to mechanism of Pseudomonas resistance in cystic fibrosis.
    Lawrence D
    Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.